The Allstate Co. (NYSE:ALL – Get Free Report) announced a quarterly dividend on Thursday, November 14th,RTT News reports. Shareholders of record on Friday, November 29th will be paid a dividend of 0.92 per share by the insurance provider on Thursday, January 2nd. This represents a $3.68 dividend on an annualized basis and a yield of 1.77%. The ex-dividend date is Friday, November 29th.
Allstate has increased its dividend payment by an average of 18.1% annually over the last three years and has raised its dividend annually for the last 14 consecutive years. Allstate has a dividend payout ratio of 19.5% indicating that its dividend is sufficiently covered by earnings. Analysts expect Allstate to earn $19.14 per share next year, which means the company should continue to be able to cover its $3.68 annual dividend with an expected future payout ratio of 19.2%.
Allstate Trading Up 0.2 %
NYSE:ALL opened at $208.19 on Thursday. The company has a market cap of $55.13 billion, a P/E ratio of 13.48, a P/E/G ratio of 1.80 and a beta of 0.48. Allstate has a 1 year low of $134.17 and a 1 year high of $209.88. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.40 and a quick ratio of 0.40. The stock’s fifty day moving average price is $192.34 and its two-hundred day moving average price is $178.57.
Insiders Place Their Bets
In other Allstate news, insider John E. Dugenske sold 36,367 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $191.38, for a total transaction of $6,959,916.46. Following the completion of the sale, the insider now directly owns 27,364 shares in the company, valued at $5,236,922.32. This represents a 57.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.80% of the stock is owned by insiders.
Analysts Set New Price Targets
ALL has been the subject of a number of analyst reports. StockNews.com lowered shares of Allstate from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 21st. Barclays raised their price target on shares of Allstate from $175.00 to $187.00 and gave the company an “underweight” rating in a report on Thursday, October 31st. Wells Fargo & Company upped their price target on shares of Allstate from $175.00 to $186.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Morgan Stanley lifted their price objective on Allstate from $220.00 to $228.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Roth Mkm restated a “buy” rating and issued a $200.00 target price on shares of Allstate in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $217.19.
Read Our Latest Research Report on Allstate
Allstate Company Profile
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. It operates in five segments: Allstate Protection; Protection Services; Allstate Health and Benefits; Run-off Property-Liability; and Corporate and Other segments.
Further Reading
- Five stocks we like better than Allstate
- The How and Why of Investing in Gold Stocks
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Utilities Stocks Explained – How and Why to Invest in Utilities
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Dividend Capture Strategy: What You Need to Know
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Allstate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allstate and related companies with MarketBeat.com's FREE daily email newsletter.